HBL Hadasit Bio Holdings

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.